Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Cellebrite DI (CLBT)

Cellebrite DI (NASDAQ: CLBT) shares swung from an early earnings-day gain to a loss of about 14% on November 12, 2026, as the Company again lowered its full-year revenue guidance. Shareholders who took losses in that reversal may have legal rights.

NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- A slide of about 14% erased an early earnings-day gain in Cellebrite DI (NASDAQ: CLBT) shares on November 12, 2026, the same day the Company's third-quarter report again lowered its full-year revenue guidance. If you held CLBT through that reversal and now have a loss, you may have legal rights. Shareholders who lost money are encouraged to submit their CLBT loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The session opened in positive territory. Cellebrite reported third-quarter revenue of $149.0 million, above a FactSet estimate of $145.8 million, along with quarterly net income of $26.7 million. Early trading reports described CLBT shares gapping higher. Later in the day, the stock was reported down approximately 14%.

The same report trimmed full-year revenue guidance again, following an earlier guidance cut in August. Cellebrite guided fourth-quarter revenue to $145 million to $150 million and left its full-year annual recurring revenue guidance unchanged. Levi & Korsinsky is investigating potential securities law violations on behalf of affected CLBT shareholders.

Bought CLBT and took a loss in the November 12 reversal? Request a confidential review of your losses or call (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.

Frequently Asked Questions About the CLBT Investigation

Q: How much did CLBT stock drop? A: Shares fell approximately 14% on November 12, 2026. The drop came after the Company's third-quarter report disclosed a further reduction to its full-year revenue guidance. Investors who bought shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Cellebrite DI made materially false or misleading statements about its revenue outlook and full-year guidance. When the Company disclosed a further reduction to its full-year revenue guidance on November 12, 2026, the stock price declined sharply.

Q: Who is eligible to participate in the CLBT investigation? A: Investors who purchased CLBT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do CLBT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate Action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any later sale dates and prices.

Q: What if I already sold my CLBT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. If you choose to participate in any resulting Action , these matters are generally handled on a contingency basis. Any attorneys' fees and expenses are subject to court approval.

Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the Investor 's country of residence.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.